CORRECTING and REPLACING – Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke

GERMANTOWN, Md., Aug. 1 (Korea Bizwire) — In a release issued yesterday by Neuralstem, Inc. (Nasdaq:CUR), please note the headline should be, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke,” rather than, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke,” as originally issued. The corrected release [...]